CEO Neil McFarlane Net Acquires $1.33M in ZVRA Shares Following Option Exercise
summarizeSummary
This Form 4 filing indicates a substantial net acquisition of Zevra Therapeutics shares by President and CEO Neil F. McFarlane. While he executed a pre-planned sale of a portion of shares, the overall activity shows a significant increase in his direct ownership through the exercise of options. This net accumulation of over $1.33 million in shares by a key executive signals strong confidence in the company's future prospects.
check_boxKey Events
-
CEO Net Acquisition
President and CEO Neil F. McFarlane net acquired $1,330,581 worth of common stock, representing a significant increase in his direct ownership.
-
Option Exercise
McFarlane exercised options for 233,334 shares on January 31, 2026, contributing to the overall increase in holdings.
-
Pre-Planned Sale
A sale of 91,000 shares totaling $853,425 was executed on February 2, 2026, under a 10b5-1 plan adopted in March 2025.
-
Equity Awards Received
McFarlane also received new awards of 125,000 Restricted Stock Units and options for 250,000 shares on January 29, 2026, as part of his compensation.
auto_awesomeAnalysis
This Form 4 filing indicates a substantial net acquisition of Zevra Therapeutics shares by President and CEO Neil F. McFarlane. While he executed a pre-planned sale of a portion of shares, the overall activity shows a significant increase in his direct ownership through the exercise of options. This net accumulation of over $1.33 million in shares by a key executive signals strong confidence in the company's future prospects.
在该文件披露时，ZVRA的交易价格为$9.36，交易所为NASDAQ，所属行业为Life Sciences，市值约为$5.3亿。 52周交易区间为$6.19至$13.16。 这份文件被评估为积极市场情绪，重要性评分为8/10。